Oppenheimer cuts ratings on Apollo and Blue Owl but says other alternative investment firms remain undervalued
Oppenheimer analysts on Monday downgraded Apollo Global Management Inc. (APO) and Blue Owl Capital Inc. (OWL) to perform from outperform after the stocks from the alternative investment managers exceeded their price targets. Oppenheimer reiterated an outperform rating on Blackstone Inc. (BX) and said KKR & Co. Inc. (KKR), Carlyle Group Inc. (CG), GCM Grosvenor (GCMG) and P10 Inc. (PX) remain undervalued. While the summer saw the successful initial public offerings of Arm Holdings Plc (ARM) and Instacart (CART), as well as the first megabillion leverage loan transaction with GTCR's acquisition of Worldpay, analysts said the sharp decline in the bond market "makes us fearful that something, somewhere will sooner or later 'break' and cause financial turmoil." They added that Instacart and Arm did not trade well after their debuts.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-09-23 0803ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks